While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
A late-stage clinical trial showed therapy combining Roche’s immunotherapy Tecentriq with two of the Swiss drugmaker’s other medicines helped people with a form of advanced melanoma.
A late-stage trial testing a combination of Bristol-Myers Squibb Co.’s cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.
Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
